Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hepatitis × Steroids × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 7 Prostatic Neoplasms 3 Plasmacytoma 2 Paraproteinemias 2 Neoplasm Metastasis 2 Leukemia, Plasma Cell 2 Breast Neoplasms 2 Spinal Cord Compression 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Myasthenia Gravis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma 1 Hepatitis 1 Hemangioma 1 Head and Neck Neoplasms 1 Gallstones 1 Common Bile Duct Neoplasms 1 Common Bile Duct Diseases 1 Colorectal Neoplasms 1 Chemical and Drug Induced Liver Injury 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Hepatocellular 1 Bone Cysts 1 Anatomic Stage IV Breast Cancer AJCC v8 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

bavituximab 1 Ursodeoxycholic Acid 1 Steroids 1 Sorafenib 1 Sofosbuvir 1 Ribavirin 1 Prednisone 1 Mycophenolic Acid 1 Methylprednisolone Hemisuccinate 1 Methylprednisolone 1 Adrenal Cortex Hormones 1 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡